Mindfulness Based Relapse Prevention Therapy in Individuals with Amphetamine Use Disorder

Phase 2

Recruiting

• Conditions: Amphetamine-type stimulants.; AMPHETAMINE-TYPE SUBSTANCE USE DISORDER; 304.40 (F1

• Registration Number: IRCT20210525051403N1
• Lead Sponsor: Self funded

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 90

Inclusion Criteria

Age between 18 and 40 years age and therefore legally eligible to consent.
A history of use of methamphetamine and a diagnosis of stimulant use disorder as described in the Mental Disorders Diagnostic and Statistical Manual (DSM-5); the passage of more than a week from complete methamphetamine detoxification and negative urine test.
Be able to speak and read Urdu, sign a written consent for the participants to take part in the study, be mindful. Apart from signing into a written agreement, they have their rights, including the protection of personal data, the immunity to physical or mental harm, and the possibility of quitting the study they wish.
All participants would go through urinalysis to make sure that they are not intoxicated

Exclusion Criteria

Unwilling to attend the meetings, absenteeism of more than two sessions, engage concurrently in other health services, and have a long-term dependency on multi-drug concurrently;
Requisite medical detoxification from any substances
Those are suffering from severe medical and neuropsychiatric complications or any psychotic illness at the time of screening for intake
Participants those are unavailable or hesitant to be a part of the study for the 20 weeks
An individual having a history of using illicit substance use (e.g. cocaine, heroin)
Already completed MBRP sessions.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To measure impulsivity in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: Barratt Impulsiveness Scale-11.;Craving in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: Penn Alcohol Craving Scale (PACS) adopted for methamphetamine.;Aggression in ATS users. Timepoint: Baseline;During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT);3-month follow-up. Method of measurement: Aggression Questionnaire (Buss & Perry, 1992).

Secondary Outcome Measures

Name	Time	Method
Self efficacy in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: General Self-Efficacy Scale (GSES).;Coping skills in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: Brief COPE inventory (Carver, 1997).;Quality of life in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: WHOQOl-BREF (WHO, 1998).;Measuring risk of relapse in ATS users. Timepoint: Baseline; the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: Stimulant Relapse Risk Scale (SRRS).